# V52 Queue: Therapeutic-Path Synthesis

Status: in-progress

V52 uses the active-time block machine, but its first value-complete target is a
therapeutic-path synthesis that combines V37 findings, restored OpenGWAS access,
and V51 structural context without reopening broad public-data discovery.

## Timing

- Block start UTC: 2026-07-10T09:43:31Z
- Active target: 6h cumulative active time
- Active session intervals:
  - 2026-07-10T09:43:31Z - open
- Wall-clock span start UTC: 2026-07-10T09:43:31Z

## Environment And Remote

- `origin`: https://github.com/sleibach/multiple-sclerosis-auto-research.git
- Local HEAD at start: `f9bbebcd25926ab8438dfe1d3fa5ecc108048183`
- `origin/main` at start: `f9bbebcd25926ab8438dfe1d3fa5ecc108048183`
- OpenGWAS token: renewed and active; POST-only checker returned HTTP 200 on
  `gwasinfo` and `tophits`; decoded expiry `2026-07-24 08:00 UTC`.
- SAP_AI_CORE_API_KEY: present; Claude/Gemini/RPT health check PASS.
- AlphaFold DB client and structural gate: to be verified in iteration guard.

## Backlog

| item | status | note |
|---|---|---|
| Write therapeutic-path synthesis report | done | `docs/reports/THERAPEUTIC_PATH_V52.md`; headline: monitoring/stratification is the honest near-term impact; no target is intervention-grade. |
| Structure-informed chr1 review: GPR25 | done | V51 AlphaFold record plus V17/V19 direction/druggability confirms structurally plausible but causally unresolved and chemically immature. |
| Structure-informed chr1 review: KIF21B | done | Retrieved AlphaFold DB `AF-O75037-F1` v6; motor-domain context is structurally interpretable but restoration/up-function direction keeps target closed. |
| Restored-OpenGWAS catch-up inventory | done | `docs/workups/genetics/RESTORED_OPENGWAS_CATCHUP_V52.md`; token active; bounded confirmed-locus rerun only. |
| Restored-OpenGWAS smoke rerun for genetics scripts | done | `scripts/v14_susie_coloc_confirmed_loci.py` reran POST-only `/ld/matrix` routes; no target verdict changed. |
| Therapeutic contradiction/convergence check | done | `knowledge_external/synthesis/V52_THERAPEUTIC_CONVERGENCE_CONTRADICTION.md`; 10 therapeutic rows reviewed, 6 convergences/context corroborations, 4 context/orthogonal rows, 0 genuine contradictions, 0 therapeutic verdict changes. |
| Validation-readiness tie-in | done | `docs/validation/THERAPEUTIC_VALIDATION_HANDOFF_V52.md`; clarifies what Gafson/Karolinska pass, immune-tone-bounded pass, fail, inconclusive, or unscoreable package means for clinical action. |
| Guard and push iteration | done | V47 provenance, V51 structural, external index, SAP health, status freshness, size/tmp guards passed; commit `f396b814` pushed to `origin/main` at 2026-07-10T09:56:54Z. |
| Structure-informed PTGER4 triage | done | AlphaFold DB `AF-P35408-F1` v6 retrieved; receptor-core structural context is compatible with tractability, but closure is confirmed because the blocker is mixed signal and direction, not lack of structure. |
| Restored-OpenGWAS ZMIZ1 bounded direction handoff | done | `docs/workups/genetics/ZMIZ1_RESTORED_OPENGWAS_HANDOFF_V52.md`; restored token can polish bounded direction manifests but does not create a ZMIZ1 target route. |
| Public-facing therapeutic summary card | done | `docs/reports/THERAPEUTIC_PATH_SUMMARY_CARD_V52.md`; compact medical-team handoff: validate monitoring first, no target intervention-grade, exact next data asks. |
| Chr1 genotype-linked data specification | done | `docs/workups/genetics/CHR1_GENOTYPE_LINKED_DATA_SPEC_V52.md`; exact future data package needed to resolve GPR25 vs KIF21B and direction/modality. |
| V52 therapeutic validation handoff | todo | Convert monitoring-first conclusion into validation-ready medical-team action items. |
| PTGER4 signal-specific reopen spec | todo | If pursued later, define exact QTL/fine-mapping/perturbation evidence needed before PTGER4 can move out of closed-transfer status. |
| Structure-aware no-go table | done | `docs/workups/genetics/STRUCTURE_AWARE_NO_GO_TABLE_V52.md`; structure sharpens feasibility but cannot override causal-gene, direction, cell-state, or modality blockers. |
| OpenGWAS renewal watch note | todo | Add a V52 operational note that token expires 2026-07-24 and targeted reruns should finish or renew before then. |

## Per-Iteration Notes

- 2026-07-10T09:43:31Z: V52 started. OpenGWAS `.env` override uses renewed JWT;
  POST-only checker passed (`gwasinfo`, `tophits`) with expiry
  `2026-07-24 08:00 UTC`. Remote aligned at `f9bbebcd`. SAP AI Core health
  check passed for Claude/Gemini/RPT.
- 2026-07-10T09:50:02Z: Wrote `docs/reports/THERAPEUTIC_PATH_V52.md`, added
  KIF21B AlphaFold DB structural record (`O75037`) and context note, reran
  V19 chr1 local reanalysis and V14 confirmed-locus SuSiE-coloc with restored
  OpenGWAS POST-only access. Therapeutic headline: monitoring/stratification is
  the strongest near-term impact; chr1 remains real biology but not
  intervention-grade.
- 2026-07-10T09:55:38Z: Guard checkpoint passed: provenance gate, structural
  synthetic fixtures, structural record audit, external Markdown/index linters,
  SAP AI Core health, V52-aware status freshness, tracked-file size guard, and
  tracked-`tmp/` guard. Preparing first V52 commit and push.
- 2026-07-10T09:56:54Z: First V52 iteration committed and pushed as
  `f396b814`; local and `origin/main` match. Continuing with therapeutic
  convergence/contradiction content rather than stopping below the 6h active
  target.
- 2026-07-10T09:59:16Z: Wrote and indexed
  `knowledge_external/synthesis/V52_THERAPEUTIC_CONVERGENCE_CONTRADICTION.md`.
  Result: no genuine therapeutic contradiction surfaced; external context
  supports validation guardrails and cautionary target closures but does not
  validate the scalar or create an intervention-grade target.
- 2026-07-10T10:01:18Z: Therapeutic convergence check committed and pushed as
  `f1573e33`; local and `origin/main` match. Continuing with validation-
  readiness tie-in.
- 2026-07-10T10:02:53Z: Wrote
  `docs/validation/THERAPEUTIC_VALIDATION_HANDOFF_V52.md` and linked it from
  the therapeutic report, validation-readiness doc, current status, and next
  actions. It keeps V42/V44 frozen and translates outcomes into medical-team
  actionability.
- 2026-07-10T10:04:01Z: Validation handoff committed and pushed as
  `91f1b780`; local and `origin/main` match. Continuing with PTGER4
  structure-informed triage.
- 2026-07-10T10:06:23Z: Retrieved PTGER4 AlphaFold DB `AF-P35408-F1` v6
  (`P35408`) and wrote
  `knowledge_external/synthesis/V52_PTGER4_ALPHAFOLD_DRUGGABILITY_CONTEXT.md`.
  Result: PTGER4 remains closed as a naive transfer target; structure sharpens
  receptor-core context but does not address mixed-signal/direction blockers.
- 2026-07-10T10:09:18Z: PTGER4 structural triage committed and pushed as
  `e9558a63`; local and `origin/main` match. Continuing with ZMIZ1
  restored-OpenGWAS bounded direction handoff.
- 2026-07-10T10:10:51Z: Wrote
  `docs/workups/genetics/ZMIZ1_RESTORED_OPENGWAS_HANDOFF_V52.md`. Result:
  restored OpenGWAS can support bounded chr10 direction-manifest polish, but
  ZMIZ1 remains a transfer-validity warning and not a therapeutic target.
- 2026-07-10T10:12:06Z: ZMIZ1 handoff committed and pushed as `6111f67f`;
  local and `origin/main` match. Continuing with public-facing therapeutic
  summary card.
- 2026-07-10T10:13:18Z: Wrote
  `docs/reports/THERAPEUTIC_PATH_SUMMARY_CARD_V52.md`, linked from the main
  therapeutic report and live navigation. It states the public-facing V52
  bottom line: validate monitoring first; no intervention-grade target yet.
- 2026-07-10T10:14:28Z: Therapeutic summary card committed and pushed as
  `a49ea3f4`; local and `origin/main` match. Continuing with chr1
  genotype-linked data specification.
- 2026-07-10T10:16:04Z: Wrote
  `docs/workups/genetics/CHR1_GENOTYPE_LINKED_DATA_SPEC_V52.md`. Result: chr1
  target work now has an exact genotype-linked immune/CSF expression/protein
  and perturbation data ask; no target is reopened without that package.
- 2026-07-10T10:17:20Z: chr1 data specification committed and pushed as
  `addb5b2b`; local and `origin/main` match. Continuing with structure-aware
  no-go table.
- 2026-07-10T10:18:37Z: Wrote
  `docs/workups/genetics/STRUCTURE_AWARE_NO_GO_TABLE_V52.md`. Result: GPR25,
  KIF21B, PTGER4, and ZMIZ1 remain no-go for target promotion until
  direction-matched biology and modality evidence arrive; AlphaFold context does
  not override grounded genetics.
